Second untreatable superbug infection found in US

Patient in New York infected with a strain of E. coli highly resistant to last-resort antibiotic treatments


A patient in New York has been infected with a strain of E. coli highly resistant to last-resort antibiotic treatments, according to an article on the Becker's Infection Control and Clinical Quality website.

This is the second U.S. patient with the untreatable superbug infection, following a Pennsylvania patient first made public last month.

The mcr-1 gene gives bacteria resistance to colistin, a last-line-of-defense antibiotic used to combat a number of resistant microorganisms.

Going into 2017, the White House has requested $1.1 billion be allocated to efforts to combat antibiotic resistance in the U.S. 

Read the article.

 

 



July 6, 2016


Topic Area: Infection Control


Recent Posts

Making the Energy Efficiency Case to the C-Suite

Hospital executives often wrestle with energy decisions made today that either free up budget for patient care or drain resources that could go elsewhere.


How to Avoid HAIs This Flu Season

There are risks surrounding hospitalizations. Here’s how to avoid them.


Design Phase Set to Begin for Hospital Annex at SUNY Upstate Medical

The design will feature a new, expanded emergency department and burn unit to serve the Central New York Region.


Building Hospital Resilience in an Era of Extreme Weather

Expert Jennifer Mahan discusses the vulnerabilities healthcare facilities face during disasters and the infrastructure strategies that keep operations running.


Ennoble Care Falls Victim to Data Breach

Their investigation into the incident is still ongoing.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.